Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Crinetics Pharmaceuticals (NASDAQ:CRNX) has outperformed the market over the past 5 years by 21.74% on an annualized basis producing an average annual return of 33.07%. Currently, Crinetics Pharmaceuticals has a market

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics (NASDAQ:TVRD)

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay Diagnostics

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The company's

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Crinetics (CRNX) Q1 2026 Earnings Transcript

This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.

This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.

Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.

Crinetics (CRNX) Q4 2025 Earnings Call Transcript

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused solely on the rare endocrine disorder Cushing’s syndrome, Corcept has evolved into a diversified clinical-stage powerhouse. While the company recently weathered a significant regulatory storm involving [...]